AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Insulet Corporation (PODD)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

280.04

-0.52 (-0.19%)

At close: Feb 18, 2025, 3:59 PM

280.71

0.24%

After-hours: Feb 18, 2025, 04:00 PM EST

undefined% (undefined)

Bid	275
Market Cap	19.64B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	5.86
PE Ratio (ttm)	47.79
Forward PE	n/a
Analyst	Buy

Ask	299
Volume	474,439
Avg. Volume (20D)	535,555
Open	280.20
Previous Close	280.56
Day's Range	270.00 - 284.40
52-Week Range	160.19 - 289.46
Beta	undefined

About PODD

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly i...

[Show more]

Industry Medical - Devices

Sector Healthcare

IPO Date May 15, 2007

Employees 3,000

Stock Exchange NASDAQ

Ticker Symbol PODD

Website https://www.insulet.com

Full Company Profile

Analyst Forecast

According to 15 analyst ratings, the average rating for PODD stock is "Buy." The 12-month stock price forecast is $285, which is an increase of 1.77% from the latest price.

Buy 86.67%

Hold 6.67%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Insulet Corporation is scheduled to release its earnings on Feb 20, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+3.68%

Insulet shares are trading higher after TD Cowen r... Unlock content with Pro Subscription

2 months ago

+3.9%

Insulet shares are trading higher amid strength in diabetes-related stocks following weight loss data from Novo Nordisk.

News

4 days ago · zacks.com

Stay Ahead of the Game With Insulet (PODD) Q4 Earnings: Wall Street's Insights on Key Metrics

Beyond analysts' top -and-bottom-line estimates for Insulet (PODD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter...

2 weeks ago · zacks.com

NVIDIA & 2 Other Profitable Stocks to Buy in February

NVIDIA, AppLovin and Insulet have been selected as the top picks with a high net income ratio.

2 weeks ago · zacks.com

Here's Why You Should Add PODD Stock to Your Portfolio Now

Insulet stays on investors' radar owing to its solid progress with Omnipod 5 and strong solvency position.

1 month ago · zacks.com

GEHC or PODD: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and Insulet (PODD). But which of these two stocks is more attractive to value investors?

1 month ago · zacks.com

PODD Stock Gains From the Launch of Omnipod 5 in Five Countries in EU

Insulet announces the launch of Omnipod 5 in five more countries in Europe, Italy, Denmark, Finland, Norway and Sweden.

1 month ago · businesswire.com

Insulet Launches Revolutionary Omnipod® 5 in Five More Countries in Europe

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced t...

1 month ago · businesswire.com

Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

1 month ago · zacks.com

GEHC vs. PODD: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical - Products sector have probably already heard of GE HealthCare Technologies (GEHC) and Insulet (PODD). But which of these two companies is the best opti...

1 month ago · fxempire.com

Heavy Interest in Insulet's Insulin Delivery Device

Sales are surging for Insulet Corporation (PODD).

2 months ago · zacks.com

Why Insulet (PODD) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Load More News